NEW YORK


,


Dec. 1, 2022


/PRNewswire/ — Levi & Korsinsky, LLP notifies investors in

Eiger BioPharmaceuticals, Inc.

(“Eiger” or the “Company”) (NASDAQ: EIGR) of a class action securities lawsuit.

CLASS DEFINITION:

The lawsuit seeks to recover losses on behalf of Eiger investors who were adversely affected by alleged securities fraud between

March 10, 2021

and

October 4, 2022

. Follow the link below to get more information and be contacted by a member of our team:

Eiger BioPharmaceuticals Class Action Lawsuit Submission Form

EIGR

investors may also contact

Joseph E. Levi, Esq.

via email

at [email protected] or

by telephone at (212) 363-7500.

CASE DETAILS:

The filed complaint alleges that defendants made false statements and/or concealed that: (i) defendants overstated Eiger’s clinical and regulatory drug development expertise; (ii) defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the Emergency Use Authorization (“EUA”) for the Company’s product candidate, peginterferon lambda ; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda’s regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

WHAT’S NEXT?

If you suffered a loss in Eiger during the relevant time frame, you have until


January 9, 2023


to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU:

If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees.

There is no cost or obligation to participate.

WHY LEVI & KORSINSKY:

Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in

the United States

.

CONTACT:


Levi & Korsinsky, LLP


Joseph E. Levi, Esq.



Ed Korsinsky, Esq.


55 Broadway, 10th Floor


New York, NY

10006


[email protected]


Tel: (212) 363-7500

Fax: (212) 363-7171


www.zlk.com

View original content to download multimedia:

https://www.prnewswire.com/news-releases/eigr-lawsuit-alert-levi–korsinsky-notifies-eiger-biopharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-301690982.html

SOURCE Levi & Korsinsky, LLP